TOKYO -- Japanese drugmaker Eisai hopes to begin clinical trials on a second Alzheimer's disease treatment in 2024, following up on the recent U.S. approval of lecanemab as its first.
Pharmaceuticals
Eisai eyes 2024 launch of trials for new Alzheimer's drug
Japanese pharmaceutical company has multiple dementia treatments in its pipeline
Eisai is in the global race to develop new treatments for dementia. (Photo courtesy of Eisai)
Read Next
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
